Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.0K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.0K
Seizures: Classification01:13

Seizures: Classification

1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

770
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
770
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

1.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

700
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
700
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

501
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
501

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of the Structure and Dynamics of Water in Aqueous Alkaline Chloride Solutions under Gigapascal Pressure by Neutron Scattering.

The journal of physical chemistry letters·2026
Same author

Association between voltage-gated sodium channel gene polymorphisms and chronic oxaliplatin-induced peripheral neuropathy in Japanese patients with colorectal cancer.

Journal of pharmaceutical health care and sciences·2026
Same author

Singular Continuous and Nonreciprocal Phonons in Quasicrystal AlPdMn.

Physical review letters·2024
Same author

Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.

Annals of palliative medicine·2023
Same author

A Joint Multitask Learning Model for Cross-sectional and Longitudinal Predictions of Visual Field Using OCT.

Ophthalmology science·2022
Same author

Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study.

Journal of clinical medicine·2022

Related Experiment Videos

[Epilepsy and law].

Masato Matsuura1

  • 1Section of Biofunctional Informatics, Tokyo Medical and Dental University.

Rinsho Shinkeigaku = Clinical Neurology
|December 1, 2012
PubMed
Summary
This summary is machine-generated.

People with epilepsy (PWE) in Japan face challenges with social resource utilization and driving regulations. Doctors suggest revising seizure-free periods and improving risk assessment to reduce accidents.

Related Experiment Videos

Area of Science:

  • Neurology
  • Public Health
  • Law

Context:

  • Japanese law extends mental health and welfare provisions to people with epilepsy (PWE).
  • PWE reportedly underutilize available social resources like financial aid for medical care and living costs.
  • Driving regulations amended in 2002 permit PWE to obtain licenses after a two-year seizure-free period.

Purpose:

  • To analyze the effectiveness of current Japanese laws and regulations concerning people with epilepsy (PWE).
  • To identify challenges in assessing fitness to drive for PWE.
  • To evaluate the impact of epilepsy on driving safety and propose improvements.

Summary:

  • In 2010, 3,373 PWE legally obtained driving licenses, with doctors assessing fitness. Key concerns include shortening the two-year seizure-free period and extending the six-month reassessment interval.
  • Difficulties in assessing seizure recurrence risk and determining reassessment timing were noted.
  • In 2010, 71 traffic accidents were attributed to epileptic seizures, with only five drivers having disclosed their condition.

Impact:

  • Urgent need for action plans, including public, patient, and professional education, to enhance regulatory compliance.
  • Potential to reduce traffic accidents involving PWE by improving assessment and adherence to regulations.
  • Highlights the intersection of epilepsy management, legal frameworks, and public safety.